References
Simonet WS, Lacey DL, Dunstan C et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319
Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in sk-n-mc neuronal cells. J Neurochem 86:126–135
DI Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340
Zauli G, Melloni E, Capitani S, Secchiero P (2009) Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:841–851
Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236–2244
Navarra P, Dello Russo C, Mancuso C, Preziosi P, Grossman A (2000) Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann NY Acad Sci 917:638–646
Wang R (2002) Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16:1792–1798
Moore PK, Bhatia M, Moochhala S (2003) Hydrogen sulfide: from the smell of the past to the gas of the future? Trends Pharmacol Sci 24:609–611
Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530
Secchiero P, Corallini F, Gonelli A et al (2007) Anti-angiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61–69
Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of aids patients are committed to apoptotic cell death in culture. AIDS 7:1049–1055
Zauli G, Re MC, Furlini G, Giovannini M, LA Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein GP120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417–421
Zauli G, Rimondi E, Stea S et al (2008) Trail inhibits osteoclastic differentiation by counteracting rankl-dependent P27KIP1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117–125
Mangan SH, Campenhout AV, Rush C, Golledge J (2007) Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 76:494–505
Zauli G, Corallini F, Bossi F et al (2007) Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110:536–543
Cross SS, Yang Z, Brown NJ et al (2006) Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118:1901–1908
Li L, Moore P (2008) Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends Pharmacol Sci 29:84–90
Szabó C (2007) Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917–993
Secchiero P, Corallini F, DI Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) Trail counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413–3419
Acknowledgments
This work was supported by a grant from FoRST—Fondazione per la Ricerca Scientifica Termale to GZ.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rimondi, E., di Iasio, M.G., Gonelli, A. et al. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 30, 1731–1735 (2012). https://doi.org/10.1007/s10637-011-9675-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-011-9675-8